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Abstract
Background Telomere length has been associated with
coronary artery disease and heart failure. We studied
whether leukocyte telomere length is associated with left
ventricular ejection fraction (LVEF) after ST-elevation
myocardial infarction (STEMI).
Methods and results Leukocyte telomere length (LTL)
was determined using the monochrome multiplex quanti-
tative PCR method in 353 patients participating in the
glycometabolic intervention as adjunct to primary percu-
taneous coronary intervention in STEMI III trial. LVEF
was assessed by magnetic resonance imaging. The mean
age of patients was 58.9 ± 11.6 years, 75 % were male. In
age- and gender-adjusted models, LTL at baseline was
significantly associated with age (beta ± standard error;
-0.33 ± 0.01; P\ 0.01), gender (0.15 ± 0.03; P\ 0.01),
TIMI flow pre-PCI (0.05 ± 0.03; P\ 0.01), TIMI
flow post-PCI (0.03 ± 0.04; P\ 0.01), myocardial blush
grade (-0.05 ± 0.07; P\ 0.01), serum glucose levels
(-0.11 ± 0.01; P = 0.03), and total leukocyte count
(-0.11 ± 0.01; P = 0.04). At 4 months after STEMI,
LVEF was well preserved (54.1 ± 8.4 %) and was not
associated with baseline LTL (P = 0.95). Baseline LTL
was associated with n-terminal pro-brain natriuretic pep-
tide (NT-proBNP) at 4 months (-0.14 ± 0.01; P = 0.02),
albeit not independent for age and gender.
Conclusion Our study does not support a role for LTL as
a causal factor related to left ventricular ejection fraction
after STEMI.
Keywords Telomeres  ST-elevation myocardial
infarction  Left ventricular ejection fraction  Metformin
Introduction
ST-segment elevation myocardial infarction (STEMI) is a
life-threatening medical condition with a high incidence in
Western societies [1]. Timely reperfusion of the culprit
artery by primary percutaneous coronary intervention (PCI)
is the cornerstone of medical treatment to improve survival
and reduce the risk of left ventricular (LV) dysfunction [2].
Nevertheless, up to 30 % of patients develop systolic LV
dysfunction after STEMI [3], which is an important pre-
dictor for clinical outcome [4]. However, the susceptibility
to develop LV dysfunction among individuals suffering
from STEMI remains partially unpredictable, even after
considering factors as ischemic time and culprit lesion
characteristics. Increasing our knowledge on these factors
might provide novel avenues for risk stratification and fu-
ture development of therapy.
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We hypothesize that telomere length might be an im-
portant factor associated with the development of LV
dysfunction after STEMI. In humans, telomeres are repe-
titive hexameric sequences (TTAGGG)n located at the
terminal end of chromosomes, which protect genes from
degradation during cell division due to the ‘end replication
problem’ [5, 6]. With each mitotic cell division, a terminal
part of the telomere is lost since DNA polymerases fail to
completely replicate the strand which begins at the 30
chromosomal end [7]. Aging is, therefore, associated with
gradual loss of telomere length. If a critical telomere length
is reached, cellular senescence or apoptosis is induced [8].
Environmental stressors, for example oxidative stress [9,
10], and inflammatory processes [11], are associated with
accelerated shortening of telomere length. Patients with
cardiovascular diseases, like coronary artery disease [12],
myocardial infarction [13], and heart failure [14] are
characterized by shorter telomeres compared to healthy
controls [6]. Telomere length has also been associated with
LVEF in octogenarians in a non-STEMI setting [15],
nevertheless PCI treatment for STEMI has been proven
safe and effective in this age group [16, 17]. In addition,
genetic variants implicated in LTL have also been associ-
ated with LVEF suggesting a potential causal relationship
[18].
We present a sub-study of the glycometabolic inter-
vention as adjunct to primary coronary intervention in
STEMI (GIPS-III) trial in which we measured leukocyte
telomere length to investigate whether baseline leukocyte




The design and primary outcomes of the GIPS-III trial have
been published previously [19, 20]. In brief, the GIPS-III
was a double-blinded, placebo-controlled trial including
380 non-diabetic STEMI patients undergoing PCI and who
were subsequently randomly assigned to metformin
(N = 191) or placebo (N = 189) treatment, twice daily for
a period of 4 months. Major exclusion criteria included (1)
known diabetes, (2) previous myocardial infarction, (3) the
need for coronary artery bypass surgery (CABG), (4)
severe renal dysfunction, and (5) standard contraindica-
tions for magnetic resonance imaging (MRI). The primary
outcome was LVEF 4 months after STEMI. After
4 months, LVEF of metformin and placebo-treated patients
was similar [20]. All investigators of the GIPS-III trial can
be found in the ‘‘Appendix.’’ The trial is registered with
clinicaltrials.gov identifier: NCT01217307.
Study outcomes
Primary study outcome was LVEF determined 4 months
after STEMI using a 3.0 T whole-body MRI (Achieva;
Philips) using a phased array cardiac receiver coil. Se-
condary outcomes were other MRI measured parameters
[left ventricular end diastolic volume (LVEDV), left ven-
tricular end systolic volume (LVESV), left ventricular end
diastolic mass (LVEDM)], and n-terminal pro-brain natri-
uretic peptide (NT-proBNP).
Telomere length measurements
Blood for DNA isolation was collected from the patients at
arrival at the catheterization laboratory (baseline) which
was used for telomere length determination. White blood
cell DNA extraction was performed by LGC genomics.
Telomere length was measured in quadruplicate on 4 dif-
ferent plates with each replicate in the same well position
on the polymerase chain reaction (PCR) plate by the
monochrome multiplex quantitative PCR method,
originally developed by Cawthon [21]. The telomere pri-
mers were TelC: 50-TGT TAG GTA TCC CTA TCC CTA
TCC CTA TCC CTA TCC CTA ACA-30 (final concen-
tration 900 nM); TelG: 50-ACA CTA AGG TTT GGG TTT
GGG TTT GGG TTT GGG TTA GTG T-30 (900 nM); the
albumin primers were AlbDgc: 50-GCC CGG CCC GCC
GCG CCC GTC CCG CCG GAA AAG CAT GGT CGC
CTG TT-30 (300 nM); AlbUgc: 50-CGG CGG CGG GCG
GCG CGG GCT GGG CGG AAA TGC TGC ACA GAA
TCC TTG-30 (300 nM). The final concentrations of the
reagentia per 10 ll reaction were 1X Titanium Taq DNA
Polymerase (Clontech Laboratories, Inc.); 1X Titanium
Taq PCR Buffer (Clontech Laboratories, Inc.); 0.2 mM of
each dNTP (Promega); 0.75X SYBR Green I nucleic acid
gel stain (Sigma-Aldrich); 1 M Betaine (Sigma-Aldrich);
1 mM DL-Dithiothreitol (Sigma-Aldrich). DNA of a hu-
man leukemia cell line (1301) with extreme long telomeres
was used as a positive control [22]. The thermal cycling
profile was done using the BioRad C1000 Touch Thermal
Cycler as follows: stage 1: 15 min at 95 C; stage 2: 2
cycles of 15 s at 94 C, 15 s at 49 C; stage 3: 32 cycles of
15 s at 94 C, 10 s at 60 C, 15 s at 72 C with signal
acquisition, 10 s at 85 C, and 15 s at 89 C with signal
acquisition. The T/S ratio was calculated by dividing the
telomere (T) signal by the signal of a reference gene (al-
bumin, S). The CFX Manager version 3.0 software was
used for generating the standard curves and analyzing the
samples. Two standard curves were generated for each
plate, one for the telomere signal and one for the albumin
signal. Each sample was assayed in triplicate; therefore
three T/S ratios were obtained for each sample and the
mean of these three T/S ratios was reported. We expect that
Clin Res Cardiol (2015) 104:812–821 813
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the mean T/S ratio is proportional to the mean telomere
length per cell. If the sample has a T/S ratio[1.0 then the
mean telomere length will be longer than the standard
DNA; if the sample has a T/S ratio \1.0, the mean
telomere length will be shorter than the standard DNA.
This T/S ratio, hereafter called leukocyte telomere length
(LTL), is a relative measurement of leukocyte telomere
content in a sample, which serves as a proxy for actual
leukocyte telomere lengths [21]. The median intra-assay
coefficients of variation were 9.4 % for T, 10.1 % for S,
and 3.4 % for the T/S ratio. Samples were excluded from
further analyses if the coefficient of variation for the T/S
ratio was[0.1 after deletion of one of the four replicate
measurements.
Statistical analysis
Continuous variables are reported as mean (standard de-
viation, SD) for normally distributed data. Since LTL and
NT-proBNP were non-normally distributed, log transfor-
mation was performed to obtain a near normal distribution.
Outliers were defined as[2 SD from the median of LTL.
For continuous and dichotomous data, we performed linear
regression analyses using LTL as dependent variable and
baseline characteristics and outcome parameters as inde-
pendent variables; categorical data were tested using ex-
panded interaction linear regression analyses. All analyses
were first performed univariately and then adjusted for age
and gender. Graphical representation of interaction ana-
lyses were performed using the ‘‘margins’’ command in
STATA. Statistical tests were performed two-tailed and a
P value of\0.05 was used as nominal level of statistical




Genomic DNA was successfully extracted from 362
(95.5 %) patients of the GIPS-III cohort. LTL was suc-
cessfully determined in 356 (98.3 %) of the DNA samples
(3 samples exhibited insufficient DNA quality, 3 samples
were excluded due to coefficient of variation [0.1 after
repeated measurement). ANOVA test revealed no sig-
nificant difference between LTL of both treatment groups
(P = 0.15). Another 3 samples were regarded as outliers
based on[2 SD deviation of the mean LTL, leaving 353
samples for the current analyses. MRI data at 4 months
after STEMI were available for 253 (71.6 %) patients of
patients whose LTL was determined. Baseline
characteristics of the study cohort are represented in
Table 1. Patients were aged on average 58.9 ± 11.6 years
old and 75.1 % was male. The majority had hypercholes-
terolemia (62.6 %) and was an active smoker (54.7 %) at
baseline. Systolic blood pressure was 134.0 ± 23.5 mmHg
and diastolic blood pressure was 84.0 ± 14.4 mmHg. The
majority (68.6 %) of the patients presented with single
vessel disease. The culprit vessel was predominantly the
right coronary artery (RCA). At baseline, NT-proBNP
levels were 80 U/L (IQR 38–179), and CK-MB levels were
16 U/L (IQR 13–24).
Associations between baseline patient characteristics
and LTL
Leukocyte telomere length was negatively associated with
age (Fig. 1). Univariate linear regression analyses revealed
a significant association between baseline LTL with age,
gender, active smoking behavior, single vessel disease,
serum creatinine, and glucose levels (Table 2). Although
univariately, active smokers seem to have longer LTL than
non-smokers, this could be explained by the large age
difference between smokers and non-smokers (54.4 ± 10.5
for smokers versus 64.3 ± 10.6 years for non-smokers).
After including age and gender in the model, only serum
glucose levels remained significantly associated with LTL.
Univariately, ‘thrombolysis in myocardial infarction’
(TIMI) flow (both pre- and post-PCI), myocardial blush
grade, and total leukocyte count were not associated with
baseline LTL; however, after adjustment for age and gen-
der, the association became significant. We tested for an
effect of age underlying these association but could not
identify a significant interaction effect (interaction coeffi-
cient myocardial blush grade = 3.2 9 10-4; 95 % confi-
dence interval (CI) -5.5 9 10-3 to 6.1 9 10-3; P = 0.91;
interaction coefficient TIMI flow pre-PCI B0.01; 95 % CI
-0.01 to 0.01; P = 0.97; interaction coefficient TIMI flow
post-PCI B0.01; 95 % CI -0.02 to 0.00; P = 0.15; inter-
action coefficient total leukocyte count = -0.14; 95 % CI
-0.29 to 0.01; P = 0.08).
Cardiac MRI at 4 months after STEMI
and associations with baseline LTL
Mean LVEF, as determined by MRI, was well preserved at
4 months after STEMI (54.1 ± 8.4 %). LVEF, left ven-
tricular end diastolic volume (LVEDV), left ventricular end
systolic volume (LVESV), left ventricular end diastolic
mass (LVEDM), and infarct size are represented in
Table 3. LTL measurement at baseline was not associated
with LVEF at 4 months (Fig. 2), neither with the other
parameters of cardiac remodeling (Table 4).
814 Clin Res Cardiol (2015) 104:812–821
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Treatment effect of metformin on LTL
We have explored the possible interaction of metformin
with LTL on LVEF at 4 months. Interaction analyses re-
vealed no significant interaction of treatment with the as-
sociation of baseline LTL and LVEF at 4 months
(interaction coefficient = 4.0; 95 % CI -5.5 to 13.5;
P = 0.41, Table 4). However, we found evidence for effect
modulation by metformin treatment on the association of
LTL with NT-proBNP at 4 months (interaction coeffi-
cient = -1.3; 95 % CI -2.5 to -0.1; P = 0.04). NT-
Table 1 Baseline characteristics
Variable Level Value
N 353
Age (years), mean (SD) 58.9 (11.6)
Gender Male 265 (75.1 %)
Female 88 (24.9 %)
Body mass index (kg/m2),
mean (SD)
26.9 (3.7)
Ethnicity Caucasian 339 (96.0 %)
Asian 10 (2.8 %)
Black 4 (1.1 %)
Hypertension No 250 (70.8 %)
Yes 103 (29.2 %)
Hypercholesterolemia No 132 (37.4 %)
Yes 221 (62.6 %)
Active smoker No 160 (45.3 %)
Yes 193 (54.7 %)
Stroke No 350 (99.2 %)
Yes 3 (0.8 %)
Previous PTCA No 349 (98.9 %)







Heart rate (bpm), mean (SD) 75.4 (16.0)
Total ischemic time (min),
median (IQR)
161 (109, 251)
Single vessel disease No 111 (31.4 %)
Yes 242 (68.6 %)
Culprit vessel LAD 135 (38.2 %)
LCX 60 (17.0 %)
RCA 158 (44.8 %)
TIMI flow grade (pre-
interventional)
0 195 (55.2 %)
1 26 (7.4 %)
2 60 (17.0 %)
3 72 (20.4 %)
TIMI flow grade (post-
interventional)
2 33 (9.3 %)
3 320 (90.7 %)
Myocardial blush grade 0 9 (2.6 %)
1 27 (7.7 %)
2 70 (20.0 %)
3 244 (69.7 %)
CK total (U/L), median (IQR) 129 (83, 208)
CK-MB (U/L), median (IQR) 16 (13, 24)
AUC CK total (U 9 h/L),
median (IQR)
1.0 9 108 (4.0 9 107,
2.3 9 108)
AUC CK-MB (U 9 h/L),
median (IQR)
















HBA1c (%), median (IQR) 5.8 (5.6, 6)
Body mass index was calculated by dividing weight (in kilograms) by
squared height (in meters). Normally distributed data are expressed as
mean (standard deviation), non-Gaussian data as median (inter-
quartile range)
AUC area under the curve, BP blood pressure, BMI body mass index,
eGFR estimate glomerular filtration rate, HF heart failure, HFrEF
heart failure with reduced ejection fraction, HFpEF heart failure with
preserved ejection fraction, hs-CRP highly sensitive C-reactive pro-
tein, IQR inter-quartile range, LAD left anterior descending coronary
artery, LCX left circumflex coronary artery, NT-pro-BNP N-terminal
pro-B-type natriuretic peptide, RCA right coronary artery, SD stan-
dard deviation, TIMI thrombolysis in myocardial infarction
Fig. 1 Scatter plot showing association between LTL and age, with
superimposed 95 % confidence interval and regression line. LTL
leukocyte telomere length. Individual data points are shown as well as
the superimposed regression line including the 95 % CI
Clin Res Cardiol (2015) 104:812–821 815
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Table 2 Association of baseline characteristics with LTL
Univariate model Multivariate model
Std. beta SE P value Std. beta SE P value
Age (years) -0.31 0.00 \0.01 -0.33 \0.01 \0.01
Gender 0.11 0.03 0.03 0.15 0.03 \0.01
Body mass index (kg/m2) \0.01 \0.01 0.99 -0.04 \0.01 0.42
Ethnicity
Caucasian 0.18 0.18
Asian 0.01 0.07 0.02 0.07
Black 0.10 0.11 0.07 0.11
Hypertension -0.04 0.03 0.48 0.02 0.03 0.73
Hypercholesterolemia 0.03 0.02 0.58 -0.02 0.02 0.74
Active smoker (y/n) 0.16 0.02 \0.01 0.02 0.03 0.72
Stroke -0.05 0.13 0.33 -0.02 0.12 0.68
Previous PTCA -0.02 0.11 0.71 \0.01 0.11 0.99
Systolic blood pressure (mmHg) -0.02 \0.01 0.77 -0.02 \0.01 0.71
Diastolic blood pressure (mmHg) 0.04 \0.01 0.44 \0.01 \0.01 0.99
Heart rate (bpm) -0.03 \0.01 0.59 -0.05 \0.01 0.34
Total ischemic time (min) 0.06 \0.01 0.26 0.07 \0.01 0.16
Single vessel disease 0.14 0.03 0.01 0.10 0.02 0.05
Culprit vessel
LAD 0.51 0.73
CX 0.07 0.03 0.06 0.03
RCA 0.03 0.03 0.02 0.02
TIMI flow (pre-PCI)
0 0.10 \0.01
1 -0.06 0.05 -0.05 0.04
2 -0.10 0.03 -0.05 0.03
3 0.05 0.03 0.05 0.03
TIMI flow (post-PCI)
2 0.20 \0.01
3 0.07 0.04 0.03 0.04
Myocardial blush grade
0 0.82 \0.01
1 0.02 0.09 -0.05 0.08
2 0.09 0.08 -0.04 0.08
3 0.11 0.08 -0.05 0.07
CK total (U/L) \0.01 \0.01 0.97 0.02 \0.01 0.71
CK-MB (U/L) -0.01 \0.01 0.92 0.01 \0.01 0.81
AUC CK (U 9 h/L) 0.03 \0.01 0.58 0.05 \0.01 0.33
AUC CK-MB (U 9 h/L) -0.02 \0.01 0.78 0.02 \0.01 0.69
Creatinine (lmol/L) -0.13 \0.01 0.02 -0.04 \0.01 0.52
NT-proBNP (ng/L) -0.04 \0.01 0.49 -0.02 \0.01 0.64
Total leukocyte count (109/L) -0.02 \0.01 0.78 -0.11 \0.01 0.04
Glucose (mmol/L) -0.15 \0.01 \0.01 -0.11 \0.01 0.03
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proBNP levels were similar for patients with different
levels of LTL after placebo treatment but in patients treated
with metformin, longer LTL was associated with lower
NT-proBNP levels (Fig. 3).
Discussion
Leukocyte telomere length has been proposed as a marker
of biological age and has been suggested to play an im-
portant role in cellular senescence or apoptosis [8]. Previ-
ously, associations have been reported between LTL with
coronary artery disease [12], heart failure [23], and LVEF
[15]. We hypothesized that LTL is associated with cardiac
remodeling after STEMI as can be reflected by LVEF at
4 months. The main finding of the present study is that we
could not find support for this hypothesis.
In our study, we did observe the well-established asso-
ciation of LTL with baseline characteristics such as the
inverse association with age [23, 24] and gender (females
having longer LTL [25]). The direction of smokers was
opposite as frequently reported (active smokers in GIPS-III
were found to have longer LTL) [22, 26] but this could be
completely explained by the large age difference between
non-smokers and smokers. These associations suggest that
our main finding is unlikely due to measurement error of
LTL. A possible explanation for the absence of an asso-
ciation between LTL and LVEF in the GIPS-III trial might
be the relatively well-preserved LVEF after STEMI.
Considering the mean LVEF of approximately 54 % after
STEMI, the variation of the primary endpoint might have
been too small to establish an association with LTL.
However, even in the absence of STEMI and the resulting
cardiac remodeling, one could speculate on an association
between LVEF and LTL. In a cohort of octogenarians
(N = 64; average age 85.2-year old) without evidence of
previous myocardial infarction, LTL was strongly and in-
dependently associated with LVEF as determined by
echocardiography [15]. In this cohort, approximately 12 %
of the observed variability in LVEF could be explained by
LTL alone. In addition, an association between LTL and
LVEF has been reported in subjects with hypertension
(N = 1106; average age 57.9-year old). A 1.5 fold larger
LTL was associated with 0.6 % increase in absolute LVEF
[18]. On the other hand, there are also several studies
Table 2 continued
Univariate model Multivariate model
Std. beta SE P value Std. beta SE P value
HBA1c (%) -0.05 0.01 0.39 -0.02 0.01 0.64
Linear regression analyses of baseline characteristics with LTL are presented for dichotomous and continuous variables; categorical variables
were tested by interaction expanded linear regression analyses. Standardized (Std.) beta, standard error (SE), and P values are shown. Multi-
variate tests were adjusted for age and gender (except for age and gender, which were only adjusted for age (gender) or gender (age). Body mass
index was calculated by dividing weight (in kilograms) by squared height (in meters)
AUC area under the curve, CK creatine kinase, CK-MB creatine kinase myocardial band, HBA1c glycated hemoglobin, LAD left anterior
descending coronary artery, LCX left circumflex coronary artery, NT-proBNP n-terminal pro-brain natriuretic peptide, PTCA percutaneous
transluminal coronary angioplasty, RCA right coronary artery, SE standard error, TIMI thrombolysis in myocardial infarction
Table 3 STEMI outcomes at 4 months after STEMI
Outcome Values
LVEF (%) 54.1 (8.4)
LVEDV (mL) 193.4 (45.1)
LVESV (mL) 90.8 (35.5)
LVEDM (g) 100.9 (23.1)
Infarct size (g) 9.3 (9.0)
NT-proBNP (ng/L) 264 (119–631)
Values are presented as mean (SD), except for NT-proBNP, which is
presented as median (IQR)
LVEF left ventricular ejection fraction, LVEDV left ventricular end
diastolic volume, LVESV left ventricular end systolic volume,
LVEDM left ventricular end diastolic mass, NT-proBNP n-terminal
pro-brain natriuretic peptide
Fig. 2 Scatter plot graph showing no association between LTL and
LVEF at 4 months with superimposed 95 % CI and regression line.
LVEF left ventricular ejection fraction, LTL leukocyte telomere
length. Individual data points are shown as well as the superimposed
regression line including the 95 % CI
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reporting a lack of an association between LTL and LVEF
in other settings. In a cohort with established heart failure
patients (N = 610; average age 66.2-year old), we did not
observe an association with LVEF [14]. In another cohort
of patients with idiopathic cardiomyopathies (N = 223;
average age 51.1-year old), LTL was also not associated
with LVEF as determined [27]. Also in subjects derived
from the general population, the absence of an association
between LTL and LVEF has been reported. In the Malmo¨
Preventive Project, a cross-sectional observational study
including 1588 subjects (average age 67.7-year old), an
association with LTL with LVEF was lacking [28]. In an
additional population-based cohort of Chinese Han people
(N = 139; average age 60.3-year old), there was also no
association with LTL and LVEF [29].
Our data contribute to the previous studies by investi-
gating a specific population (STEMI) in which the role of
LTL might be more prominent. However, our data
demonstrate that even in the setting of STEMI and the
subsequent remodeling process of the heart, LTL does not
seem to be associated and, therefore, is unlikely to be in-
volved. Biomarkers for predicting outcomes in coronary
heart disease outcomes have been reported [30], but the
present study does not support the use of LTL as a
biomarker in the setting of STEMI. The well-preserved
LVEF 4 months after STEMI, which is the result of the
high level of acute care in our STEMI network [31], could
have nullified the potential role of LTL in STEMI outcome
prediction. Besides LVEF, we also took into account pos-
sible relationships between LTL and other outcome pa-
rameters. In our study, lower levels of NT proBNP, often
elevated in heart failure, were associated with longer LTL
only in the metformin group. Further studies are needed to
clarify if this association can be attributed to the effect of
metformin. Other studies report the predictive value of
cardiopulmonary exercise testing in heart failure patients
with previous myocardial infarction [32]. In experimental
mice model, physical activity prevented senescence of
leukocytes and increased telomerase activity was seen in
endurance athletes [33]. In this study, physical activity was
not measured; therefore, we cannot assess the effect of
physical activity on LTL. Worsening renal function and
acute kidney injury are associated with increased mortality
in STEMI patients [34]. In our study, serum creatinine was
associated with shorter LTL; however, after adjusted for
age and sex, this relationship did not remain significant.
The major limitation of our study that needs to be
considered is that the cells we investigated are leukocytes.
Therefore, we cannot exclude an important role of telomere
length in other cell types, e.g., cardiomyocytes or
Table 4 Associations of baseline LTL measurement with STEMI outcomes 4 months after STEMI
Univariate analyses Multivariate analyses Treatment interaction
Std. beta SE P value Std. beta SE P value P value
LVEF (%) 0.00 \0.01 0.95 -0.01 \0.01 0.88 0.41
LVEDV (mL) 0.09 \0.01 0.17 0.04 \0.01 0.55 0.37
LVESV (mL) 0.06 \0.01 0.37 0.03 \0.01 0.63 0.31
LVEDM (g) 0.08 \0.01 0.20 0.12 \0.01 0.07 0.18
Infarct size (g) 0.02 \0.01 0.77 0.03 \0.01 0.59 0.30
Log NT-proBNP (ng/L) -0.14 0.01 0.02 -0.07 0.01 0.25 0.04
Univariate and age ? gender-adjusted analyses are presented. P for interaction represents P value of interaction between outcome parameter,
LTL and metformin treatment. Standardized (Std.) beta, standard error (SE), and P values are shown. Multivariate tests were adjusted for age and
gender. P for interaction represents the statistical test for outcome modification by metformin or placebo treatment
LVEF left ventricular ejection fraction, LVEDV left ventricular end diastolic volume, LVESV left ventricular end systolic volume, LVEDM left
ventricular end diastolic mass, NT-proBNP n-terminal pro-brain natriuretic peptide
Fig. 3 Interaction between baseline LTL and levels of NT-proBNP at
4 months after Metformin or Placebo treatment. LTL leukocyte
telomere length. Linear prediction represents the predicted NT-
proBNP for both metformin as well as placebo-treated patients.
Regression line and 95 % CI are shown
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endothelial cells [35]. For practical (and ethical) reasons, it
is not feasible to study cardiomyocytes of STEMI patients.
Another limitation is that our analyses are based on a single
LTL measurement. Therefore, we cannot exclude that LTL
measurements in the stable setting or cross-sectionally at
time of LVEF determination are associated with LVEF.
This remains to be determined. In this study, PCR method
was used for feasibility reasons; however, the gold standard
for LTL assessment is FACS-FlowFISH which more
specifically can differentiate between different cell sub-
populations within the peripheral blood [36]. Finally,
telomere length is only one of the parameters of telomere
biology related to apoptosis and senescence. Telomere bi-
ology is more complex than telomere length alone. It also
involves many regulatory and stabilizing protein com-
plexes (sheltering) interacting with the telomere DNA se-
quence to protect the DNA [6, 37]. The exclusion of
telomere length as a factor associated with LVEF does not
exclude a role of telomere biology per se. The strengths of
our study include that we have executed the current study
within the framework of a clinical trial using the golden
standard to determine LVEF.
In conclusion, LTL measured in the setting of STEMI is
not associated with cardiac remodeling or LVEF as deter-
mined by MRI after 4 months. Our study does not lend
support for a role of LTL as a causal factor in LV re-
modeling or for the use as a biomarker to predict clinical
outcome in patients with acute myocardial infarction.
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